GlassScriptPhysician profile
Patricia Suzanne Maska
NPI 1942275672
$8,224.65
in general payments reported to CMS, 2019-2025
58 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,767 · 2020: $1,188 · 2021: $658 · 2022: $895 · 2023: $1,440 · 2024: $430 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.47 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.20 | 2019-2025 | |
| Amgen INC. | $530.53 | 2019-2025 | Aimovig, Uplizna |
| Ucb, INC. | $491.05 | 2019-2025 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $487.38 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $438.54 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $397.78 | 2019-2023 | Vumerity, Avonex, Plegridy |
| Sunovion Pharmaceuticals INC. | $303.68 | 2019-2022 | |
| Allergan, INC. | $280.34 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $271.19 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $243.09 | 2019-2025 | Kisunla |
| Avanir Pharmaceuticals, INC. | $222.94 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $222.84 | 2019-2025 | Crexont, Rytary |
| Adamas Pharmaceuticals, INC. | $196.13 | 2019-2020 | |
| Eisai INC. | $184.46 | 2019-2025 | |
| Axsome Therapeutics, INC. | $180.87 | 2023-2025 | Symbravo, Sunosi |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Maska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.